All In Biotech

Drug Trial Radar · NCT05409066

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 549 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

549

Actual

Start

Sep 20, 2022

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • EpcoritamabDrug

    Subcutaneous Injection

  • RituximabDrug

    Intravenous Infusion

  • LenalidomideDrug

    Oral Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Best Overall Response (BOR)Time frame: Up to approximately 2 years and 3 months
  2. Progression-Free Survival (PFS)Time frame: Up to approximately 2 years and 3 months

Locations

273 sites in 30 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center - North Campus /ID# 228862

    Tucson, Arizona

  • University of Arkansas for Medical Sciences /ID# 227198

    Little Rock, Arkansas

  • Alta Bates Summit Medical Center for Research /ID# 229428

    Berkeley, California

  • Beverly Hills Cancer Center /ID# 231535

    Beverly Hills, California

  • Long Beach Memorial Medical Ct /ID# 228997

    Long Beach, California

  • University of Southern California /ID# 227195

    Los Angeles, California

  • Valkyrie Clinical Trials /ID# 268502

    Los Angeles, California

  • Duplicate_Emory University /ID# 227299

    Atlanta, Georgia

  • Hawaii Cancer Care - Waterfront Plaza /ID# 262448

    Honolulu, Hawaii

  • Northwestern University Feinberg School of Medicine /ID# 227248

    Chicago, Illinois

  • Goshen Center for Cancer Care /ID# 227189

    Goshen, Indiana

  • Community Health Network, Inc. /ID# 259756

    Indianapolis, Indiana

  • Our Lady Of The Lake Regional Medical Center /ID# 251393

    Baton Rouge, Louisiana

  • University of Maryland, Baltimore /ID# 227191

    Baltimore, Maryland

  • Massachusetts General Hospital /ID# 245233

    Boston, Massachusetts

  • UMass Memorial Medical Center /ID# 227323

    Worcester, Massachusetts

  • Henry Ford Hospital /ID# 227250

    Detroit, Michigan

  • St. Luke's Hospital - Chesterfield /ID# 247817

    Chesterfield, Missouri

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 251220

    Billings, Montana

  • Morristown Medical Center /ID# 231427

    Morristown, New Jersey

  • Roswell Park Cancer Institute /ID# 239128

    Buffalo, New York

  • NYU Langone Hospital - Long Island /ID# 253343

    Mineola, New York

  • NYU Laura and Isaac Perlmutter Cancer Center /ID# 227322

    New York, New York

  • Icahn School of Medicine at Mount Sinai /ID# 227181

    New York, New York

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 227193

    New York, New York

  • East Carolina University - Brody School of Medicine /ID# 227192

    Greenville, North Carolina

  • University of Oklahoma, Stephenson Cancer Center /ID# 227325

    Oklahoma City, Oklahoma

  • Baylor Sammons Cancer Center /ID# 261584

    Dallas, Texas

  • Texas Oncology - Northeast Texas /ID# 265890

    Tyler, Texas

  • Intermountain Healthcare LDS Hospital /ID# 259948

    Salt Lake City, Utah

  • Virginia Commonwealth University Medical Center Main Hospital /ID# 227211

    Richmond, Virginia

  • Hospital Privado Universitario - Hospital Privado Centro Medico de Cordoba S.A. /ID# 229701

    Córdoba, Argentina

  • Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares /ID# 232124

    Santa Fe, Argentina

  • Fundaleu /Id# 229700

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

  • Duplicate_CEMIC /ID# 229697

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

  • Royal Prince Alfred Hospital /ID# 239272

    Camperdown, New South Wales, Australia

  • Nepean Hospital /ID# 239093

    Kingswood, New South Wales, Australia

  • Townsville University Hospital /ID# 231124

    Douglas, Queensland, Australia

  • Peninsula Private Hospital /ID# 238796

    Frankston, Victoria, Australia

  • Fiona Stanley Hospital /ID# 231122

    Murdoch, Western Australia, Australia

Showing 40 of 273 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.